Poltreg Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
34
- Stock Symbol
-
PTG
- Share Price
-
$4.89
- (As of Friday Closing)
Poltreg General Information
Description
Poltreg SA is a biotechnology company is a Polish biotechnology company developing therapies using regulatory T cells (TREGS) - which have applications in the field of autoimmunity - including in the treatment of type 1 diabetes (CT1), multiple sclerosis and others. It focuses on the clinical trials and the commercialization of a patented method of T-regulator lymphocyte prolife ration for the treatment of type 1 diabetes in children. The company's operations are mainly conducted in Poland.
Contact Information
Website
www.poltreg.bioCorporate Office
- Botaniczna 20
- Gdańsk, 80-298
- Poland
Corporate Office
- Botaniczna 20
- Gdańsk, 80-298
- Poland
Poltreg Stock Performance
As of 13-Nov-2026, Poltreg’s stock price is $4.89. Its current market cap is $28.9M with 5.92M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.89 | $4.85 | $4.31 - $8.08 | $28.9M | 5.92M | 4.43K | -$1.37 |
Poltreg Financials Summary
As of 30-Jun-2026, Poltreg has a trailing 12-month revenue of $65.9K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 26,620 | 27,085 | 31,006 | 40,892 |
| Revenue | 66 | 0 | 88 | 333 |
| EBITDA | (5,103) | (5,493) | (4,049) | (3,648) |
| Net Income | (6,714) | (6,909) | (4,696) | (3,224) |
| Total Assets | 19,998 | 20,266 | 24,892 | 31,848 |
| Total Debt | 1,989 | 2,117 | 1,938 | 2,053 |
Poltreg Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Poltreg Comparisons
Industry
Financing
Details
Poltreg Competitors (18)
One of Poltreg’s 18 competitors is Egle Therapeutics, a Venture Capital-Backed company based in Suresnes, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Egle Therapeutics | Venture Capital-Backed | Suresnes, France | ||||
| Lyell Immunopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Enterome | Venture Capital-Backed | Paris, France | ||||
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA |
Poltreg Patents
Poltreg Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025219454-A1 | Preproinsulin tolerogenic fragments for treating and monitoring type 1 diabetes | Pending | 18-Apr-2024 | ||
| EP-4544303-A1 | Methods for monitoring and for assessing the efficacy of treg cell therapies | Pending | 11-Sep-2023 | ||
| US-20260185983-A1 | Methods for monitoring and for assessing the efficacy of treg cell therapies | Pending | 11-Sep-2023 | ||
| WO-2025056144-A1 | Methods for monitoring and for assessing the efficacy of treg cell therapies | Inactive | 11-Sep-2023 | ||
| EP-3985105-A1 | Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population | Pending | 16-Oct-2020 | A61K40/48 |
Poltreg Signals
Poltreg Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Poltreg ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Services
Subindustry
Rank
Percentile
Poltreg FAQs
-
When was Poltreg founded?
Poltreg was founded in 2015.
-
Where is Poltreg headquartered?
Poltreg is headquartered in Gdańsk, Poland.
-
What is the size of Poltreg?
Poltreg has 34 total employees.
-
What industry is Poltreg in?
Poltreg’s primary industry is Drug Discovery.
-
Is Poltreg a private or public company?
Poltreg is a Public company.
-
What is Poltreg’s stock symbol?
The ticker symbol for Poltreg is PTG.
-
What is the current stock price of Poltreg?
As of 13-Nov-2026 the stock price of Poltreg is $4.89.
-
What is the current market cap of Poltreg?
The current market capitalization of Poltreg is $28.9M.
-
What is Poltreg’s current revenue?
The trailing twelve month revenue for Poltreg is $65.9K.
-
Who are Poltreg’s competitors?
Egle Therapeutics, Lyell Immunopharma, Enterome, Seres Therapeutics, and Sangamo Therapeutics are some of the 18 competitors of Poltreg.
-
What is Poltreg’s annual earnings per share (EPS)?
Poltreg’s EPS for 12 months was -$1.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process